Trade GeoVax Labs, Inc. - GOVX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0264 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.6118 |
| Open | 1.6518 |
| 1-Year Change | -29.97% |
| Day's Range | 1.5518 - 1.6718 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 1.6518 | 0.0100 | 0.61% | 1.6418 | 1.6918 | 1.5418 |
| Feb 20, 2025 | 1.6118 | -0.0800 | -4.73% | 1.6918 | 1.7018 | 1.6118 |
| Feb 19, 2025 | 1.6918 | -0.0300 | -1.74% | 1.7218 | 1.7518 | 1.6918 |
| Feb 18, 2025 | 1.7318 | 0.0200 | 1.17% | 1.7118 | 1.7718 | 1.6918 |
| Feb 14, 2025 | 1.7218 | 0.0800 | 4.87% | 1.6418 | 1.7418 | 1.6418 |
| Feb 13, 2025 | 1.6918 | -0.0200 | -1.17% | 1.7118 | 1.7218 | 1.6218 |
| Feb 12, 2025 | 1.7118 | 0.1400 | 8.91% | 1.5718 | 1.7318 | 1.5518 |
| Feb 11, 2025 | 1.5218 | 0.0000 | 0.00% | 1.5218 | 1.6118 | 1.4918 |
| Feb 10, 2025 | 1.5418 | -0.1500 | -8.87% | 1.6918 | 1.6918 | 1.5318 |
| Feb 7, 2025 | 1.6718 | -0.0300 | -1.76% | 1.7018 | 1.7518 | 1.6518 |
| Feb 6, 2025 | 1.6918 | -0.0400 | -2.31% | 1.7318 | 1.7418 | 1.6418 |
| Feb 5, 2025 | 1.7218 | 0.0100 | 0.58% | 1.7118 | 1.8018 | 1.6818 |
| Feb 4, 2025 | 1.7218 | -0.0200 | -1.15% | 1.7418 | 1.7618 | 1.6918 |
| Feb 3, 2025 | 1.7518 | -0.1000 | -5.40% | 1.8518 | 2.0518 | 1.6918 |
| Jan 31, 2025 | 1.8918 | -0.0500 | -2.57% | 1.9418 | 1.9418 | 1.8518 |
| Jan 30, 2025 | 1.9318 | 0.0600 | 3.21% | 1.8718 | 1.9618 | 1.8718 |
| Jan 29, 2025 | 1.8718 | -0.0600 | -3.11% | 1.9318 | 1.9318 | 1.8418 |
| Jan 28, 2025 | 1.9218 | 0.0100 | 0.52% | 1.9118 | 1.9418 | 1.8518 |
| Jan 27, 2025 | 1.9218 | -0.1000 | -4.95% | 2.0218 | 2.1318 | 1.8518 |
| Jan 24, 2025 | 2.0618 | -0.1000 | -4.63% | 2.1618 | 2.2218 | 2.0418 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GeoVax Labs, Inc. Company profile
About Geovax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
1900 Lake Park Drive
Suite 380
SMYRNA
GEORGIA 30080
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com